Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Brain Imaging

Brain Imaging

Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Blood-brain Barrier

The Blood-brain Barrier

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Room temperature "optical nanodiamond hyperpolarizer": Physics, design, and operation.

The Review of scientific instruments·2020

Same author

Hyperpolarized relaxometry based nuclear T<sub>1</sub> noise spectroscopy in diamond.

Nature communications·2019

Same author

Wide dynamic range magnetic field cycler: Harnessing quantum control at low and high fields.

The Review of scientific instruments·2019

Same author

Enhanced dynamic nuclear polarization via swept microwave frequency combs.

Proceedings of the National Academy of Sciences of the United States of America·2018

Same author

No increased death toll for long-term menopausal hormone therapy.

Climacteric : the journal of the International Menopause Society·2017

Same author

Menopausal hormone therapy for primary prevention: why the USPSTF is wrong.

Climacteric : the journal of the International Menopause Society·2017

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Hormone therapy and brain tumors.

¹Department of Medicine 'T', Ichilov Hospital, Tel-Aviv, Israel.

Climacteric : the Journal of the International Menopause Society

|November 12, 2010

Summary

Postmenopausal hormone therapy may increase meningioma risk by 30-80% in women, though the absolute risk remains low due to the rarity of this brain tumor.

Area of Science:

Neuro-oncology
Endocrinology
Epidemiology

Background:

Meningiomas are rare brain tumors with a higher incidence in women.
Female sex hormones are suspected to influence brain tumor development.
Previous studies suggest a link between hormone therapy and meningioma risk.

Purpose of the Study:

To evaluate the association between postmenopausal hormone therapy and the risk of meningioma and glioma.
To assess the clinical significance of hormone therapy's impact on meningioma incidence.

Main Methods:

Analysis of prospective, large-scale studies.
Comparison of meningioma and glioma incidence rates in hormone therapy users versus non-users.
Calculation of relative and absolute excess risks.

More Related Videos

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

Related Experiment Videos

Last Updated: Jun 6, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

Main Results:

Postmenopausal hormone therapy was associated with a 30-80% increased risk of meningioma diagnosis.
No increased risk of glioma was observed with hormone therapy.
The absolute excess risk of meningioma attributed to hormone therapy is clinically insignificant due to the low baseline incidence.

Conclusions:

While postmenopausal hormone therapy may elevate meningioma risk, the overall clinical impact is minimal.
The findings underscore the importance of considering baseline disease incidence when interpreting risk factors.
Further research may explore specific hormone formulations or durations of use.